Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Oral Surgery
Reference11 articles.
1. Zhan Z-J, Yao W-Y, Zhang F, Qiu W-Z, Liao K-, Feng J-H, et al. The optimal second-line systemic treatment model for recurrent and/or metastatic head and neck squamous cell carcinoma: a bayesian network meta-analysis. Front Immunol 2021;12:719650.
2. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression;Ferris;Oral Oncol,2018
3. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial;Cohen;Ann Oncol,2017
4. The pattern of care of use of nivolumab in head and neck cancers - audit from a tertiary cancer centre;Patil;Clin Oncol,2021
5. Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer;Joshi;Oral Oncol,2017
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3